文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

长期免疫抑制治疗与感染性休克ICU患者不良预后无关:PACIFIC研究

Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study.
PubMed 文献 · Crit Care · 2023-09-02
一句话结论回顾性多中心研究显示,长期免疫抑制治疗(除外化疗)的感染性休克患者ICU死亡率24% vs 25%,与未暴露者无显著差异。

PACIFIC研究为回顾性流行病学多中心研究,纳入8个感染性休克随机对照试验高入组中心。暴露组来自7项近期RCT筛选失败日志中因免疫抑制治疗被排除者(103例),非暴露组为同一批RCT安慰剂组患者(330例)。暴露组免疫抑制原因包括器官移植45例(44%)和系统性疾病58例(56%)。ICU死亡率暴露组24% vs 非暴露组25%(p=0.9);单因素和多因素分析中免疫抑制治疗均与更高的ICU死亡率(OR 0.95,95%CI 0.56-1.58,p=0.86;OR 1.13,95%CI 0.61-2.05,p=0.69)或3个月死亡率(OR 1.13,95%CI 0.69-1.82,p=0.62;OR 1.36,95%CI 0.78-2.37,p=0.28)无关。结论认为长期免疫抑制治疗(除外化疗)与感染性休克患者ICU及3个月死亡率无显著升高或降低相关。

要点

  • 感染性休克ICU患者中,长期免疫抑制治疗(除外化疗)者ICU死亡率为24%,非暴露者为25%(p=0.9)。
  • 多因素分析中免疫抑制治疗与ICU死亡率无关(OR 1.13,95%CI 0.61-2.05,p=0.69)。
  • 多因素分析中免疫抑制治疗与3个月死亡率无关(OR 1.36,95%CI 0.78-2.37,p=0.28)。
  • 暴露组免疫抑制原因:器官移植45例(44%)、系统性疾病58例(56%)。
  • 暴露组选自7项RCT筛选失败日志中因免疫抑制治疗被排除者,非暴露组为同一批RCT安慰剂组患者。

适用人群与场景

  • 因感染性休克收入ICU的患者,来自8个感染性休克随机对照试验高入组中心。
  • 暴露组为7项近期RCT筛选失败日志中因免疫抑制治疗被排除者(103例),免疫抑制原因包括器官移植(n=45,44%)或系统性疾病(n=58,56%)。
  • 非暴露组为同一批RCT安慰剂组患者(330例)。
  • 长期免疫抑制治疗的定义中排除化疗。

研究设计与关键结果

  • 研究类型:回顾性流行病学多中心研究,8个感染性休克RCT高入组中心参与,共纳入433例患者。
  • 暴露组103例,非暴露组330例;ICU死亡率暴露组24% vs 非暴露组25%(p=0.9)。
  • 单因素分析:免疫抑制治疗与ICU死亡率无关(OR 0.95,95%CI 0.56-1.58,p=0.86);与3个月死亡率无关(OR 1.13,95%CI 0.69-1.82,p=0.62)。
  • 多因素分析:免疫抑制治疗与ICU死亡率无关(OR 1.13,95%CI 0.61-2.05,p=0.69);与3个月死亡率无关(OR 1.36,95%CI 0.78-2.37,p=0.28)。

证据类型、等级与局限

  • 证据类型:回顾性流行病学多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,长期免疫抑制治疗(除外化疗)与感染性休克患者ICU及3个月死亡率无显著升高或降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Except in a few retrospective studies mainly including patients under chemotherapy, information regarding the impact of immunosuppressive therapy on the prognosis of patients admitted to the intensive care unit (ICU) for septic shock is scarce. Accordingly, the PACIFIC study aimed to asses if immunosuppressive therapy is associated with an increased mortality in patients admitted to the ICU for septic shock.

METHODS: This was a retrospective epidemiological multicentre study. Eight high enroller centres in septic shock randomised controlled trials (RCTs) participated in the study. Patients in the "exposed" group were selected from the screen failure logs of seven recent RCTs and excluded because of immunosuppressive treatment. The "non-exposed" patients were those included in the placebo arm of the same RCTs. A multivariate logistic regression model was used to estimate the risk of death.

RESULTS: Among the 433 patients enrolled, 103 were included in the "exposed" group and 330 in the "non-exposed" group. Reason for immunosuppressive therapy included organ transplantation (n = 45 [44%]) or systemic disease (n = 58 [56%]). ICU mortality rate was 24% in the "exposed" group and 25% in the "non-exposed" group (p = 0.9). Neither in univariate nor in multivariate analysis immunosuppressive therapy was associated with a higher ICU mortality (OR: 0.95; [95% CI 0.56-1.58]: p = 0.86 and 1.13 [95% CI 0.61-2.05]: p = 0.69, respectively) or 3-month mortality (OR: 1.13; [95% CI 0.69-1.82]: p = 0.62 and OR: 1.36 [95% CI 0.78-2.37]: p = 0.28, respectively).

CONCLUSIONS: In this study, long-term immunosuppressive therapy excluding chemotherapy was not associated with significantly higher or lower ICU and 3-month mortality in patients admitted to the ICU for septic shock.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Vaidie J, Peju E, Jandeaux LM, et al. Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study. Crit Care. 2023. PMID: 37660107. doi:10.1186/s13054-023-04626-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。